

Amanda Shreders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3641728/publications.pdf>

Version: 2024-02-01

12
papers

210
citations

1937457

4
h-index

1372474

10
g-index

12
all docs

12
docs citations

12
times ranked

409
citing authors

#	ARTICLE	IF	CITATIONS
1	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
2	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
3	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	1.6	20
4	Emerging therapeutic agents for lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 138.	6.9	77
5	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
6	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenström Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	0.6	2
7	Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia (ITP): The Mayo Clinic Experience. <i>Blood</i> , 2016, 128, 3735-3735.	0.6	4
8	Unique Clinical Epidemiologic Risk Factors Are Associated with Distinct Methylation Subgroups in Newly-Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1719-1719.	0.6	1
9	Hemophagocytic Lymphohistiocytosis: Retrospective Analysis for Prognostic Factors. <i>Blood</i> , 2015, 126, 4615-4615.	0.6	3
10	Using Whole Exome Sequencing to Identify Genetic Variation and Polymorphisms Associated with Graft Versus Host Disease in Allogeneic Stem Cell Transplant Recipients. <i>Blood</i> , 2015, 126, 5414-5414.	0.6	2
11	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 1839-1839.	0.6	1
12	Socio-Demographic Parameters Including Race, As Predictors of Depression in Patients with Hematologic Malignancies. <i>Blood</i> , 2015, 126, 4517-4517.	0.6	0